DGIdb - RISPERIDONE Drug Record

RISPERIDONE chembl:CHEMBL85 Approved

Alternate Names:

RISPERDAL M-TAB
PERSERIS KIT
LY03004
R-64766
R-64-766
RCN-3028
RISPERIDONE
RISPERDAL CONSTA LONG ACTING
LY-03004
RISPERDAL CONSTA
R-64,766
N05AX08
RISPERDAL
RISPERDAL M
RCN3028
RISPERDAL QUICKLET
RISPERIDONUM
RISPERDAL®
RISPERIDONA
SEQUINAN
RISPOLEPT
RISPERIN
RISPOLIN
RISPERDONE
rxcui:35636
chembl:CHEMBL85
pubchem.compound:5073
chemidplus:106266-06-2
drugbank:00734

Drug Info:

FDA Approval	1993
Drug Class	small molecule
Drug Indications	Antipsychotic Agents
Drug Class	antipsychotic agents
Year of Approval	1993

(5 More Sources)

Publications:

Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J
Gassó P et al., 2009, A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms., Pharmacogenomics J
Leysen et al., 1994, Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity., J Clin Psychiatry
Megens et al., 1994, Survey on the pharmacodynamics of the new antipsychotic risperidone., Psychopharmacology (Berl.)
Saiz-Rodríguez M et al., 2018, Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants., Basic Clin Pharmacol Toxicol
Wang R et al., 2018, ABCB1 1199G > A Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics., DNA Cell Biol
Vandenberghe F et al., 2015, Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort., Clin Pharmacokinet
Suzuki Y et al., 2014, Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia., Pharmacogenomics J
Choong E et al., 2013, Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects., J Clin Psychopharmacol
Stevenson JM et al., 2016, Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes., Transl Psychiatry
Lü et al., 2004, [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]., Di Yi Jun Yi Da Xue Xue Bao
Erbağci et al., 2001, Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment., Mediators Inflamm.
Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
Fang et al., 1999, Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4., Naunyn Schmiedebergs Arch. Pharmacol.
Delacrétaz A et al., 2017, Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs., Gene
Perez-Iglesias et al., 2008, Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment., J Clin Psychopharmacol
Wei Z et al., 2013, Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy., J Clin Psychopharmacol
Canton et al., 1994, Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics., Neurosci. Lett.
Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.
Dos Santos-Júnior A et al., 2016, Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents., Int J Endocrinol
Ma X et al., 2014, HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis., Int J Psychiatry Clin Pract
Houston JP et al., 2012, Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia., J Clin Psychiatry
Risselada AJ et al., 2012, Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study., Pharmacogenomics J
Opgen-Rhein C et al., 2010, Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample., Pharmacogenomics
Ujike H et al., 2008, Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study., J Clin Psychiatry
Mulder H et al., 2009, HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study., J Clin Psychopharmacol
De Luca V et al., 2007, HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis., Hum Psychopharmacol
Mulder H et al., 2007, The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia., J Clin Psychopharmacol
Corena-McLeod M, 2015, Comparative Pharmacology of Risperidone and Paliperidone., Drugs R D
Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
Naiker et al., 2006, Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat., Eur. J. Pharmacol.
Lane et al., 2004, Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function., Int. J. Neuropsychopharmacol.
Remington et al., 2006, A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone., Am J Psychiatry
Fenton et al., 2005, Risperidone: a review of its use in the treatment of bipolar mania., CNS Drugs
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Catafau et al., 2006, Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response., Psychiatry Res
Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
Sukasem C et al., 2016, Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders., J Clin Psychopharmacol
López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
Roke Y et al., 2013, The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys., Pharmacogenet Genomics
Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J
Hong CJ et al., 2010, Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment., Pharmacogenet Genomics
Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
Yasui-Furukori N et al., 2008, Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients., Prog Neuropsychopharmacol Biol Psychiatry
Jönsson EG et al., 1999, Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers., Mol Psychiatry
Batra S, 1976, Unconjugated estradiol in the myometrium of pregnancy., Endocrinology
Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
Pohjalainen T et al., 1998, The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers., Mol Psychiatry
Monteleone P et al., 2009, Management of schizophrenia with obesity, metabolic, and endocrinological disorders., Psychiatr Clin North Am
Hoenicka J et al., 2010, The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine., Biol Psychiatry
Blum K et al., 1990, Allelic association of human dopamine D2 receptor gene in alcoholism., JAMA
Kraschewski A et al., 2009, Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function., Pharmacogenet Genomics
Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol
Doehring A et al., 2009, Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution., Pharmacogenet Genomics
Munafò MR et al., 2009, Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial., Nicotine Tob Res
Le Foll B et al., 2009, Genetics of dopamine receptors and drug addiction: a comprehensive review., Behav Pharmacol
Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
David SP et al., 2008, Genetic variation in the dopamine pathway and smoking cessation., Pharmacogenomics
Thelma B et al., 2008, Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics., Pharmacogenomics
Blum K et al., 1991, Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism., Alcohol
Huang W et al., 2009, Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample., Neuropsychopharmacology
Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
Smith L et al., 2008, Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review., Am J Epidemiol
Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
Swan GE et al., 2005, Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR., Pharmacogenomics J
Young et al., 2004, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele., Br J Psychiatry
Xu K et al., 2004, Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations., Arch Gen Psychiatry
Neville MJ et al., 2004, Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1., Hum Mutat
Johnstone EC et al., 2004, Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch., Pharmacogenetics
Yamanouchi Y et al., 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone., Pharmacogenomics J
Ritchie T et al., 2003, Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics., Neurochem Res
Li T et al., 2002, Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects., Am J Med Genet
Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
Schäfer M et al., 2001, Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene., Am J Psychiatry
Suzuki A et al., 2000, The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients., Pharmacogenetics
Mihara K et al., 2000, Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene., Psychopharmacology (Berl)
Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem
Keks et al., 1999, Risperidone (Risperdal): clinical experience with a new antipsychosis drug., Expert Opin Investig Drugs
Uchida et al., 2007, Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine., Life Sci.
Maffioletti E et al., 2020, Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients., Drug Dev Res
Angelucci F et al., 2009, Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study., J Alzheimers Dis
Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
Atmaca et al., 2003, Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics., J Clin Psychiatry
Gregoor JG et al., 2011, Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting., Pharmacogenomics
Calarge CA et al., 2009, Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents., Psychiatr Genet
Crisafulli C et al., 2012, Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics., Eur Arch Psychiatry Clin Neurosci
Wei Z et al., 2012, A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients., J Psychopharmacol
Kinkead et al., 2000, Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain., J. Pharmacol. Exp. Ther.
Hongkaew Y et al., 2018, UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder., Pharmacogenomics J
Cousein et al., 2007, P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model., Prog. Neuropsychopharmacol. Biol. Psychiatry
Xiong Y et al., 2014, A pharmacogenetic study of risperidone on chemokine (C-C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients., Prog Neuropsychopharmacol Biol Psychiatry
Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
Becker et al., 2008, Expression of mRNA of neurotrophic factors and their receptors are significantly altered after subchronic ketamine treatment., Med Chem
Lane HY et al., 2008, RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia., J Clin Psychopharmacol
Vázquez-Bourgon J et al., 2010, Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis., Psychiatry Res
Fijal BA et al., 2009, Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia., Pharmacogenomics J
Fernø et al., 2006, Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs., BMC Neurosci
Cabaleiro T et al., 2014, Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers., Hum Psychopharmacol
Zhao QZ et al., 2012, Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study., Psychiatr Genet

RISPERIDONE GRID2

Interaction Score: 2.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26905411

Sources:
PharmGKB
RISPERIDONE GRM7

Interaction Score: 2.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26905411

Sources:
PharmGKB
RISPERIDONE PPA2

Interaction Score: 1.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE MSANTD1

Interaction Score: 1.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE ANKK1

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26872113 23859574 23851570 20714340 18926547 18855532 18579277 18180754 18086475 17767146

Sources:
PharmGKB
RISPERIDONE CCL2

Interaction Score: 0.75

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24495780

Sources:
PharmGKB
RISPERIDONE LEP

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12755665 26880915 23799528 21510767 19873684

Sources:
NCI PharmGKB
RISPERIDONE DRD2

Interaction Score: 0.44

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

Trial Name -

PMIDs:
16730699 15140279 16513859 15907153 11752352 17059881 11132243 9918131 28673279 26872113 23859574 23851570 20714340 20375926 20194480 18579277 10395223 991813 9858029 9713903 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 17105675 16513877 16123753 15830237 15694263 15492764 15286066 15184239 15146457 15077009 14610521 12587665 11920858 11505224 11329406 10862524 10823405 21421319 25943458

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
RISPERIDONE GRM3

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19451915

Sources:
PharmGKB
RISPERIDONE EIF2AK4

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24751813

Sources:
PharmGKB
RISPERIDONE HTR2C

Interaction Score: 0.36

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist

Direct Interaction yes

PMIDs:
7898773 11132243 27217270 26880915 25152019 22967772 20680028 20504252 19997080 19193342 19142101 17702092 17632216 25943458

Sources:
ChemblInteractions PharmGKB
RISPERIDONE MC4R

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27217270 23920449 23799528 22566560

Sources:
PharmGKB
RISPERIDONE EPM2A

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27092952

Sources:
PharmGKB
RISPERIDONE NTS

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10991962

Sources:
NCI
RISPERIDONE TNFRSF11A

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE TJP1

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE RABEP1

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28694205

Sources:
PharmGKB
RISPERIDONE SH2B1

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28694205

Sources:
PharmGKB
RISPERIDONE HRH4

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23422377

Sources:
PharmGKB
RISPERIDONE HTR6

Interaction Score: 0.2

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
19997080

Sources:
PharmGKB
RISPERIDONE GHRL

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18480685

Sources:
NCI
RISPERIDONE HTR2A

Interaction Score: 0.14

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist

PMIDs:
11132243 15992090 17316700 15907153 32462699 23859574 19997080 19494443 25943458

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB
RISPERIDONE NTF3

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18473918

Sources:
NCI
RISPERIDONE CNR1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23799528 20631561 20107430

Sources:
PharmGKB
RISPERIDONE UGT1A7

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE UGT1A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE HRH3

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21652606

Sources:
PharmGKB
RISPERIDONE UGT1A10

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE FASN

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17052361

Sources:
NCI
RISPERIDONE FAAH

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20631561

Sources:
PharmGKB
RISPERIDONE CYP1A1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10048600

Sources:
NCI
RISPERIDONE COMT

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22935916 19451915

Sources:
PharmGKB
RISPERIDONE UGT1A8

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE DRD3

Interaction Score: 0.09

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
19997080 19506579 7520908 7531353

Sources:
PharmGKB
RISPERIDONE UGT1A6

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE UGT1A3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE UGT1A4

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE UGT1A9

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE SLC6A4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23859574 20031235

Sources:
PharmGKB
RISPERIDONE UGT1A1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29955115

Sources:
PharmGKB
RISPERIDONE HTR1A

Interaction Score: 0.06

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
11132243 22120873

Sources:
PharmGKB
RISPERIDONE GRIN2B

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23859574

Sources:
PharmGKB
RISPERIDONE TNF

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15567770 11545247

Sources:
NCI
RISPERIDONE CYP2E1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE CYP1B1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29723928 29443543 26129906 24589909 23609392 19997080

Sources:
PharmGKB
RISPERIDONE AKT1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18855532

Sources:
PharmGKB
RISPERIDONE NR1I2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26129906 23609392

Sources:
PharmGKB
RISPERIDONE RGS4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18204343

Sources:
PharmGKB
RISPERIDONE ADRB2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE HTT

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE CYP2C19

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25042870

Sources:
PharmGKB
RISPERIDONE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC FDA
RISPERIDONE KCNH2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RISPERIDONE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17337319

Sources:
NCI

TEND: RISPERIDONE
- Version: 01-August-2011
Alternate Names:

RISPERIDONE Primary Drug Name

Drug Info:

Year of Approval 1993

Drug Class antipsychotic agents

Publications:
TdgClinicalTrial: RISPERIDONE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antipsychotic Agents

Drug Class small molecule

FDA Approval 1993

Publications:

NCI: RISPERIDONE

Version: 14-September-2017

Alternate Names:

C29416 NCI drug code

Drug Info:

Publications:

Fernø et al., 2006, Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs., BMC Neurosci

Atmaca et al., 2003, Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics., J Clin Psychiatry

Fang et al., 1999, Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4., Naunyn Schmiedebergs Arch. Pharmacol.

DTC: RISPERIDONE
- Version: 02-September-2020
Alternate Names:

CHEMBL85 ChEMBL Drug ID

Drug Info:

Publications:

Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem

PharmGKB: risperidone

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J

Gassó P et al., 2009, A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms., Pharmacogenomics J

Saiz-Rodríguez M et al., 2018, Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants., Basic Clin Pharmacol Toxicol

TTD: Risperidone
- Version: 2020.06.01
Alternate Names:

D01AZG TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL85
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL85
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Risperidone
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	Dopamine D2 receptor antagonist
Trial Name	-

Mechanism of Interaction	Serotonin 2c (5-HT2c) receptor antagonist
Direct Interaction	yes

Trial Name	-
Novel drug target	Established target
Mechanism of Interaction	Serotonin 2a (5-HT2a) receptor antagonist

RISPERIDONE Drug Record

RISPERIDONE chembl:CHEMBL85 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26905411

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26905411

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26872113 23859574 23851570 20714340 18926547 18855532 18579277 18180754 18086475 17767146

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24495780

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12755665 26880915 23799528 21510767 19873684

Sources: NCI PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Dopamine D2 receptor antagonist Trial Name -

Sources: DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19451915

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24751813

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist Direct Interaction yes

PMIDs: 7898773 11132243 27217270 26880915 25152019 22967772 20680028 20504252 19997080 19193342 19142101 17702092 17632216 25943458

Sources: ChemblInteractions PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27217270 23920449 23799528 22566560

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27092952

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10991962

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28694205

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28694205

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23422377

Sources: PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26905411

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26905411

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26872113 23859574 23851570 20714340 18926547 18855532 18579277 18180754 18086475 17767146

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24495780

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12755665 26880915 23799528 21510767 19873684

Sources:
NCI PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Dopamine D2 receptor antagonist

Trial Name -

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
19451915

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24751813

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist

Direct Interaction yes

PMIDs:
7898773 11132243 27217270 26880915 25152019 22967772 20680028 20504252 19997080 19193342 19142101 17702092 17632216 25943458

Sources:
ChemblInteractions PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27217270 23920449 23799528 22566560

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27092952

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10991962

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28694205

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28694205

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23422377

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
19997080

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18480685

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist

PMIDs:
11132243 15992090 17316700 15907153 32462699 23859574 19997080 19494443 25943458

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18473918

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23799528 20631561 20107430

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB